Gene Editing

6 articles

Editorial illustration for CRISPR's Expanding Role: Beyond Gene Editing in Diagnostics and Epigenetic Control
Life & Biology

CRISPR's Expanding Role: Beyond Gene Editing in Diagnostics and Epigenetic Control

CRISPR technology has evolved significantly beyond gene editing, now offering powerful applications in rapid disease diagnostics and precise epigenetic control of gene expression without altering DNA sequences. Its versatility continues to expand into areas like RNA editing and live-cell imaging, promising broad biotechnological advancements.

David Grossman·October 1, 2026
Scientists using advanced CRISPR technology to edit a DNA strand in a futuristic laboratory, symbolizing precision gene editing for medical breakthroughs.
Explainers

What Are CRISPR Gene Editing Mechanisms and Medical Applications?

An 18-year-old with a rare immune disorder recently received the first-ever prime editing treatment.

Marcus Cole·September 11, 2026
A split cinematic image symbolizing the ethical debate around gene editing, showing a DNA helix and human embryo on one side, and a hopeful future with diverse people on the other.
Explainers

What are the ethical considerations of gene editing technologies?

Two new studies are using base editing on human embryos, a practice legal in the UK and US.

Marcus Cole·August 14, 2026
A split visual contrasting the promise of gene editing with its ethical uncertainties, featuring a DNA helix and a shadowed human silhouette with question marks.
Life & Biology

Why "Designer Babies" Divide Us: Heritability, Not the Technology Itself

The controversy surrounding "designer babies" stems from two key questions: whether genetic changes will be passed to future generations and if they aim to treat disease or select for desired traits, rather than the editing technology itself.

Marcus Cole·June 17, 2026
Diverse group of executives in a modern biotech boardroom discussing genetic sequences and financial data, symbolizing leadership changes and innovation.
Cosmos & Space

STAT Plus Reports on Major Executive Leadership Changes

Dr. Anya Sharma, former head of R&D at BioGen Corp, a major pharmaceutical player, abruptly left her post to become CEO of GenePath, a gene-editing startup that recently secured $150M in Series B fund

David Grossman·June 13, 2026
Close-up cinematic view of the CRISPR-Cas9 complex precisely editing a DNA double helix, symbolizing advancements in genetic modification and disease treatment.
Explainers

CRISPR-Cas9 vs. Prime Editing: From Genetic Scissors to a Word Processor

This article compares CRISPR-Cas9, a gene-editing tool that cuts DNA, with Prime Editing, a more advanced system that functions like a "search and replace" for genetic code. It explores their mechanisms, applications, and the challenges of off-target effects and delivery.

Marcus Cole·June 5, 2026